BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 2642814)

  • 1. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.
    Spellacy WN; Ellingson AB; Tsibris JC
    Fertil Steril; 1989 Jan; 51(1):71-4. PubMed ID: 2642814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of metabolic effects of a triphasic formulation containing norethindrone in normal women studied prospectively.
    Toth EL; Ryan EA
    Contraception; 1988 Jun; 37(6):549-54. PubMed ID: 3293908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose and insulin levels after six months of treatment with a triphasic oral contraceptive containing ethinyl estradiol and norethindrone.
    Spellacy WN; Ellingson AB; Tsibris JC
    J Reprod Med; 1989 Aug; 34(8):540-2. PubMed ID: 2681750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
    Spellacy WN
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
    Schilling LH; Bolding OT; Chenault CB; Chong AP; Fleury F; Forrest K; Glick HI; Hasson HM; Heil CG; London RS
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1264-8. PubMed ID: 2655451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.
    Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
    Contraception; 1988 Jul; 38(1):27-35. PubMed ID: 3139358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women.
    Percival-Smith RK; Morrison BJ; Sizto R; Abercrombie B
    Contraception; 1987 Feb; 35(2):179-87. PubMed ID: 3595143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of desogestrel on carbohydrate metabolism.
    Shoupe D
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1041-7. PubMed ID: 8447358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three triphasic oral contraceptives now available in U.S.
    Contracept Technol Update; 1985 Jan; 6(1):1-2, 4. PubMed ID: 12279912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of carbohydrate metabolism in women using a triphasic oral contraceptive containing norethindrone and ethinyl estradiol for 3 months.
    Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
    Am J Obstet Gynecol; 1988 Oct; 159(4):877-9. PubMed ID: 3052079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinyl estradiol.
    Spellacy WN; Tsibris JC; Hunter-Bonner DL; Smalling S; Chez RA; Angel JL; O'Brien WF
    Contraception; 1992 Jun; 45(6):533-9. PubMed ID: 1617962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.